Implantica publishes Year-end Report, January - December 2023 (Q4)
VADUZ, Liechtenstein, Feb. 16, 2024 /PRNewswire/ -- RefluxStoptm - Gaining speed, breaking boundaries and going global
Significant events in the fourth quarter of 2023
Selected U.S. surgeons begin the standardized RefluxStoptm surgery training program
in preparation for Cadaver Usability study during Q1 2024
from over 10 key centers in U.S.
results to be used in our PMA application to FDA
Successful 2nd Annual RefluxStoptm Users Meeting
> 50 participants attended
surgeons and GIs from U.S., Canada, U.K. and across Europe
RefluxStoptm cost-effectiveness research received top recognition at ISPOR, leading European health-economics conference
key finding: RefluxStoptm more cost-effective than the competition
economic analyses for 4 additional countries completed
RefluxStoptm prominently featured at Annual European Foregut Society (EFS) congress in Milan
successful symposium on RefluxStoptm by 8 leading GERD surgeons & GIs from Austria, Germany, Switzerland, Italy, U.K. and U.S.
Significant events after the end of the period
First-ever public tender win for RefluxStoptm achieved by Ospedale di Moncalieri Turin, Italy
3-year public tender
hospital to be funded full list price by public healthcare system
Added 9 new leading reflux centers since beginning of Q4
25 RefluxStoptm centers in our target markets in Europe at the beginning of the year
>650 patients successfully operated in Europe
Live RefluxStoptm surgery performed at the 34th Congress of Digestive System Surgery in Rome
nearly 2,000 surgeons attended
streamed by up to 100,000 online, nearly 90,000 international viewers
Two new key clinical and health-economics peer-reviewed papers published during Q4
health-economics paper, budget impact analysis of RefluxStoptm in U.K.
clinical paper, RefluxStoptm results in large hiatal hernia patients
Fourth quarter financial summary
Net sales increased 110% to TEUR 508 (242).
Adjusted gross margin amounted to 92% (96%).
Operating loss (EBIT) increased to TEUR 6,942 (5,108).
Loss after tax amounted to TEUR 8,734 (4,747).
Basic and diluted loss per Class A share amounted to EUR 0.12 (0.07).
Cash as at the end of the period amounted to MEUR 87.9.
Full year financial summary
Net sales increased 67% to TEUR 1,408 (842).
Adjusted gross margin amounted to 94% (96%).
Operating loss (EBIT) increased to TEUR 21,840 (18,447).
Loss after tax amounted to TEUR 24,502 (21,361).
Basic and diluted loss per Class A share amounted to EUR 0.34 (0.30).
Telephone conference
Implantica will hold a teleconference on 16 February 2024 at 15:00 (CET) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference:
numbers to the teleconference will be received by registering on the link below. After the registration, you will be provided phone numbers and a conference ID to access the conference
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company's Certified Adviser is FNCA Sweden AB, [email protected]
This information is information that Implantica AG is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-02-16 08:00 CET.
About Implantica
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStoptm, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.
OKX, a leading Web3 technology company, today announced the integration of Side Protocol with the OKX Wallet. Side Protocol is a cross-chain middleware protocol designed to enable seamless communication and asset transfer between heterogeneous...
OKX, a leading Web3 technology company, today announced the integration of Biturbo with the OKX Wallet. Bitrubo is an innovative layer 2 solution that brings the power of Ethereum's smart contracts to the Bitcoin network. Biturbo is designed as an...
Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against SSR Mining...
Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 21, 2024 to file lead plaintiff applications in a securities class action lawsuit against Shoals...
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lincoln National Corporation ("Lincoln National" or "the Company") and certain of its...
TSX VENTURE COMPANIES
BULLETIN V2024-1211
ALPHAMIN RESOURCES CORP. ("AFM")BULLETIN TYPE: Declaration of DividendBULLETIN DATE: April 26, 2024TSX Venture Tier 2 Company
The Issuer has declared the following dividend:
Dividend Amount per Common...